Autoimmune Disease Diagnosis Market Has Evolved Significantly In Healthcare Industry

What This Report Will Provide?

This study involved four major activities in estimating the current size of the autoimmune disease diagnosis market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Expected Revenue Growth:

[150 Pages Report] The global autoimmune disease diagnosis market size is expected to grow from USD 6.3 billion by 2025 from USD 4.1 billion in 2020, at a CAGR of 8.9%.

Major Growth Boosters:

This industry is experiencing significant growth due to the high incidence of autoimmune diseases, increasing awareness about autoimmune diseases, and the growth in research on autoimmune diseases.

Download PDF Brochure:

Recent Development:

In 2019, Cambridge Life Sciences Limited launched ZEUS IFA Test Systems in the US.

In 2019, PerkinElmer, Inc. received approval from the US FDA EUROIMMUN Anti-Tissue Transglutaminase ELISA to help clinicians confirm or exclude a celiac disease diagnosis.

In 2019, Exagen Inc. extended its agreement with GSK for a third year to drive greater awareness about challenges facing lupus diagnosis and management.

Key Questions Addressed in The Report:

1. Who are the top 10 players operating in the global autoimmune disease diagnosis market?
2. What are the drivers, restraints, opportunities, and challenges in the autoimmune disease diagnosis Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of autoimmune disease diagnosis in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?

Regional Growth Analysis:

The autoimmune disease diagnosis market has been analyzed for North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2019, Europe held the largest share of the market, followed by Asia Pacific. The rising incidences of chronic diseases, the increasing geriatric population in this region are the major factors driving the growth of the autoimmune disease diagnosis industry in Europe.

Request Sample Report:

Key Players:

The prominent players operating in autoimmune disease diagnosis market include Thermo Fisher Scientific (US), Siemens (Germany), Abbott (US), Danaher (US), Bio-Rad Laboratories (US), Grifols (Spain), Trinity Biotech (Ireland), Werfen (Spain), HYCOR Biomedical (US), EUROIMMUN AG (Germany), Oncimmune (UK), HTG Molecular Diagnostics (US), Seramun Diagnostica GmbH (Germany), Exagen Inc. (US), Cambridge Life Sciences Limited (UK), A. Menarini Diagnostics s.r.l (Italy), ORGENTEC Diagnostika (Germany), KRONUS (US), and AESKU GROUP GMBH & CO. KG (Germany).

Siemens AG (Germany) is one of the leading players in the autoimmune disease diagnosis industry in 2019. The company offers a broad product portfolio across the globe. Over the years, the company has maintained its leading position in the market.